Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

CardioInsight Technologies (Cleveland, OH) a commercial-stage medical device company focused on non-invasive electrocardiographic mapping technology, closed a $7.5 Series C financing. Participants were not disclosed.

BiO2 Medical (San Antonio, TX) a clinical-stage medical device company focused on catheters for pulmonary embolism in critical care patients, closed a $13.7M Series B financing. Participants include Incyte Capital and Pasadera Capital.

ImaginAb (Inglewood, CA) a clinical-stage biopharmaceutical company focused on re-engineered therapeutic antibody fragments against biologic targets for diagnostic imaging with Positron Emission Tomography scans for management of cancer and autoimmune disease, closed a $12.5M Series B financing. Participants include Novartis Venture Funds, Merieux Developpement, Nextech Invest, Cycad Group and Momentum Biosciences.

Relievant Medsystems (Redwood City, CA) a clinical-stage medical device company focused on a device for radio frequency nerve ablation for chronic axial low back pain, closed a $30M Series D financing. Participants include New Enterprise Associates, Morgenthaler Ventures, Emergent Medical Partners, Canaan Partners and Onset Ventures.

Genalyte (San Diego, CA) a clinical-stage medical device company focused on next-generation multiplexing technology, hardware and software for antibody, protein and nucleic acid assays for autoimmune diseases and other diseases, closed a $11.8M Series A financing. Participants include Redmile Group and Claremont Creek Ventures.

Stemgent (Cambridge, MA) a commercial-stage biopharmaceutical company focused on stem cell reagents and tools for stem cell researchers, closed a $6.3M Series C financing. Participants include HealthCare Ventures and Morganthaler Partners.

Phosphate Therapeutics (London, United Kingdom) a clinical-stage biopharmaceutical company focused on small molecules phosphate binders for hyperphosphatemia and renal failure, closed a $13.8M Series A financing. Participants include Inventages Venture Capital.

S.E.A. Medical Systems (Santa Clara, CA) a development-stage medical device company focused on IV drug, concentration and diluent monitoring devices for safety and prevention of drug errors, closed a $3M Series B financing. Participants include JK&B Capital.

Mevion Medical Systems (Littleton, MA) a commercial-stage medical device company focused on proton beam radiotherapy device for cancer, closed a $45M Series G financing. Participants include ProQuest Investment, Caxton Heath Life Sciences, Venrock and CHL Medical Partners.

CN Creative (United Kingdom) a development-stage medical device company focused on electronic nicotine delivery devices and other nicotine replacement therapies for nicotine addiction and smoking cessation, closed a $3.1M Series A financing. Participants include Advent Life Sciences.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.

Pulse Therapeutics (St. Louis, MO) a development-stage medical device company focused on vascular drug delivery device for blood clots in stroke patients , closed a $3.1M Series B financing. Participants include BioGenerator.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...